Predictive value of immunological markers in systemic sclerosis.
anti-Scl70
anticentromere
antinuclear antibodies
immunological profile
paraneoplastic
systemic sclerosis
Journal
Experimental and therapeutic medicine
ISSN: 1792-1015
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
05
05
2021
accepted:
04
06
2021
entrez:
4
8
2021
pubmed:
5
8
2021
medline:
5
8
2021
Statut:
ppublish
Résumé
Systemic sclerosis (SSc) is a collagenosis characterized by excessive deposition of collagen in the skin and viscera, in a background of immune disorder. The immunological profile of SSc often shows elevated levels of antinuclear antibodies (ANAs). However, many authors have identified cases of SSc having normal ANA levels, framed as paraneoplastic SSc. Among patients with negative ANAs in our group, we did not identify any neoplastic process that could support this hypothesis. The extended detection of autoantibodies is extremely useful in establishing the subset of SSc. Thus, anti-Scl70 antibodies are specific for the diffuse subset of SSc, while anticentromere antibodies (ACAs) have specificity for a limited subset. However, studies have shown the existence of cases of diffuse SSc having high titers of ACAs and cases of limited SSc with high titers of anti-Scl70 antibodies. This indicates an inconsistent association between the disease subset and the autoantibodies specific to each subset. Our study found a more balanced consistency between disease subsets and autoantibodies specific for each subset. Therefore, the percentages of patients having an immunological profile inconsistent with the subset of SSc, are lower than those found by other authors. This observation opens the perspective of larger studies on the immunological profile in SSc.
Identifiants
pubmed: 34345276
doi: 10.3892/etm.2021.10426
pii: ETM-0-0-10426
pmc: PMC8311248
doi:
Types de publication
Journal Article
Langues
eng
Pagination
994Informations de copyright
Copyright: © Bobeica et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Arthritis Rheum. 1997 Nov;40(11):1984-91
pubmed: 9365087
Exp Ther Med. 2019 Aug;18(2):955-959
pubmed: 31384329
J Eur Acad Dermatol Venereol. 2018 Apr;32(4):e159
pubmed: 29080317
Lipids Health Dis. 2020 May 6;19(1):85
pubmed: 32375792
Am J Ther. 2018 Nov/Dec;25(6):e679-e680
pubmed: 28614088
Diagnostics (Basel). 2020 Jul 16;10(7):
pubmed: 32708558
Br J Rheumatol. 1998 Jan;37(1):39-45
pubmed: 9487249
J Cutan Med Surg. 2017 Sep/Oct;21(5):442
pubmed: 28920471
Am J Ther. 2018 Jul/Aug;25(4):e497-e498
pubmed: 28328785
Exp Ther Med. 2020 Jul;20(1):61-67
pubmed: 32508995
J Rheumatol. 1988 Feb;15(2):202-5
pubmed: 3361530
Medicina (Kaunas). 2019 Oct 30;55(11):
pubmed: 31671689
Arthritis Rheum. 1988 Feb;31(2):196-203
pubmed: 3348823
J Dtsch Dermatol Ges. 2007 Nov;5(11):977-84
pubmed: 17976138
Exp Ther Med. 2019 Aug;18(2):943-948
pubmed: 31384327
Ann Dermatol Venereol. 2018 Jan;145(1):33-36
pubmed: 28917576
Z Rheumatol. 2020 Dec;79(10):1057-1066
pubmed: 32040755
Exp Ther Med. 2021 Jan;21(1):79
pubmed: 33363590
J Eur Acad Dermatol Venereol. 2018 Sep;32(9):e346-e347
pubmed: 29524256
Exp Ther Med. 2021 Jan;21(1):77
pubmed: 33363588
Dermatol Online J. 2002 Jun;8(1):3
pubmed: 12165213
J Eur Acad Dermatol Venereol. 2019 Jan;33(1):e46-e47
pubmed: 29959784
J Am Acad Dermatol. 2018 Apr;78(4):682-693
pubmed: 29208416
Clin Med (Lond). 2016 Feb;16(1):55-60
pubmed: 26833515
J Mal Vasc. 2016 Dec;41(6):365-370
pubmed: 27751625
J Rheumatol. 2015 Jan;42(1):8-10
pubmed: 25554803